Skip to main content
Erschienen in: Journal of Neuro-Oncology 3/2013

01.12.2013 | Clinical Study

The differential diagnosis of pilocytic astrocytoma with atypical features and malignant glioma: an analysis of 16 cases with emphasis on distinguishing molecular features

verfasst von: Matthew D. Cykowski, Richard A. Allen, Angela C. Kanaly, Kar-Ming Fung, Roxanne Marshall, Arie Perry, Ethan D. Stolzenberg, S. Terence Dunn

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Rare pilocytic astrocytomas (PA) have atypical histologic and clinicoradiologic features that raise the differential diagnosis of glioblastoma. Whether ancillary studies can supplement histopathologic examination in placing these cases accurately on the spectrum of WHO Grade I PA to higher-grade glioma is not always clear, partly because these cases are not common. Here, ten PAs with atypical clinicoradiologic and histologic features and six pediatric glioblastoma multiforme (pGBMs) were analyzed for BRAF V600E, IDH1, IDH2, and TP53 mutations. Ki-67, p53, and p16 protein expression were also examined by immunohistochemistry. BRAF–KIAA1549 fusion status was assessed in the PA subgroup. The rate of BRAFKIAA1549 fusion was high in these PAs (5/7 tumors) including four extracerebellar examples. A single BRAF V600E mutation was identified in the fusion-negative extracerebellar PA of a very young child who succumbed to the disease. TP53 mutations were present only in malignant gliomas, including three pGBMs and one case designated as PA with anaplastic features (with consultation opinion of pGBM). IDH1 and IDH2 were wild type in all cases, consistent with earlier findings that IDH mutations are not typical in high-grade gliomas of patients ≤14 years of age. Immunohistochemical studies showed substantial overlap in Ki-67 labeling indices, an imperfect correlation between p53 labeling and TP53 mutation status, and complete p16 loss in only two pGBMs but in no PAs. These results suggest that (a) BRAFKIAA1549 fusion may be common in PAs with atypical clinicoradiologic and histologic features, including those at extracerebellar sites, (b) BRAF V600E mutation is uncommon in extracerebellar PAs, and (c) TP53 mutation analysis remains a valuable tool in identifying childhood gliomas that will likely behave in a malignant fashion.
Literatur
1.
Zurück zum Zitat Burger PC, Scheithauer BW, Vogel FS (2002) Surgical pathology of the nervous system and its coverings, 4th edn. Churchill Livingstone, New York Burger PC, Scheithauer BW, Vogel FS (2002) Surgical pathology of the nervous system and its coverings, 4th edn. Churchill Livingstone, New York
4.
Zurück zum Zitat Perry A, Brat DJ (2010) Practical surgical neuropathology: a diagnostic approach. Churchill Livingstone, Philadelphia Perry A, Brat DJ (2010) Practical surgical neuropathology: a diagnostic approach. Churchill Livingstone, Philadelphia
5.
Zurück zum Zitat Pollack IF, Hamilton RL, Finkelstein SD, Campbell JW, Martinez AJ, Sherwin RN, Bozik ME, Gollin SM (1997) The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res 57(2):304–309PubMed Pollack IF, Hamilton RL, Finkelstein SD, Campbell JW, Martinez AJ, Sherwin RN, Bozik ME, Gollin SM (1997) The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res 57(2):304–309PubMed
6.
Zurück zum Zitat Lin A, Rodriguez FJ, Karajannis MA, Williams SC, Legault G, Zagzag D, Burger PC, Allen JC, Eberhart CG, Bar EE (2012) BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. J Neuropathol Exp Neurol 71(1):66–72. doi:10.1097/NEN.0b013e31823f2cb0 PubMedCrossRef Lin A, Rodriguez FJ, Karajannis MA, Williams SC, Legault G, Zagzag D, Burger PC, Allen JC, Eberhart CG, Bar EE (2012) BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. J Neuropathol Exp Neurol 71(1):66–72. doi:10.​1097/​NEN.​0b013e31823f2cb0​ PubMedCrossRef
7.
Zurück zum Zitat Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121(3):397–405. doi:10.1007/s00401-011-0802-6 PubMedCrossRef Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121(3):397–405. doi:10.​1007/​s00401-011-0802-6 PubMedCrossRef
8.
9.
Zurück zum Zitat Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27(25):4150–4154. doi:10.1200/JCO.2009.21.9832 PubMedCrossRef Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27(25):4150–4154. doi:10.​1200/​JCO.​2009.​21.​9832 PubMedCrossRef
10.
Zurück zum Zitat Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773. doi:10.1056/NEJMoa0808710 PubMedCrossRef Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773. doi:10.​1056/​NEJMoa0808710 PubMedCrossRef
11.
Zurück zum Zitat Pollack IF, Hamilton RL, Sobol RW, Nikiforova MN, Lyons-Weiler MA, Laframboise WA, Burger PC, Brat DJ, Rosenblum MK, Holmes EJ, Zhou T, Jakacki RI (2011) IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children’s Oncology Group. Childs Nerv Syst 27(1):87–94. doi:10.1007/s00381-010-1264-1 PubMedCrossRef Pollack IF, Hamilton RL, Sobol RW, Nikiforova MN, Lyons-Weiler MA, Laframboise WA, Burger PC, Brat DJ, Rosenblum MK, Holmes EJ, Zhou T, Jakacki RI (2011) IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children’s Oncology Group. Childs Nerv Syst 27(1):87–94. doi:10.​1007/​s00381-010-1264-1 PubMedCrossRef
12.
Zurück zum Zitat Tuominen VJ, Ruotoistenmaki S, Viitanen A, Jumppanen M, Isola J (2010) ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res 12(4):R56. doi:10.1186/bcr2615 PubMedCrossRef Tuominen VJ, Ruotoistenmaki S, Viitanen A, Jumppanen M, Isola J (2010) ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res 12(4):R56. doi:10.​1186/​bcr2615 PubMedCrossRef
13.
Zurück zum Zitat Raabe EH, Lim KS, Kim JM, Meeker A, Mao XG, Nikkhah G, Maciaczyk J, Kahlert U, Jain D, Bar E, Cohen KJ, Eberhart CG (2011) BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model. Clin Cancer Res 17(11):3590–3599. doi:10.1158/1078-0432.CCR-10-3349 PubMedCrossRef Raabe EH, Lim KS, Kim JM, Meeker A, Mao XG, Nikkhah G, Maciaczyk J, Kahlert U, Jain D, Bar E, Cohen KJ, Eberhart CG (2011) BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model. Clin Cancer Res 17(11):3590–3599. doi:10.​1158/​1078-0432.​CCR-10-3349 PubMedCrossRef
14.
Zurück zum Zitat Cykowski MD, Allen RA, Fung K-M, Harmon MA, Dunn ST (2012) Pyrosequencing of IDH1 and IDH2 mutations in brain tumors and non-neoplastic conditions. Diagn Mol Pathol 21:214–220PubMedCrossRef Cykowski MD, Allen RA, Fung K-M, Harmon MA, Dunn ST (2012) Pyrosequencing of IDH1 and IDH2 mutations in brain tumors and non-neoplastic conditions. Diagn Mol Pathol 21:214–220PubMedCrossRef
15.
Zurück zum Zitat Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, Teague JW, Campbell PJ, Stratton MR, Futreal PA (2011) COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39((Database issue)):D945–D950. doi:10.1093/nar/gkq929 PubMedCrossRef Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, Teague JW, Campbell PJ, Stratton MR, Futreal PA (2011) COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39((Database issue)):D945–D950. doi:10.​1093/​nar/​gkq929 PubMedCrossRef
16.
Zurück zum Zitat Kim YH, Nonoguchi N, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Mariani L, Giangaspero F, Tanaka Y, Nakazato Y, Vital A, Mittelbronn M, Perry A, Ohgaki H (2012) Frequent BRAF gain in low-grade diffuse gliomas with 1p/19q loss. Brain Pathol 22(6):834–840. doi:10.1111/j.1750-3639.2012.00601.x PubMedCrossRef Kim YH, Nonoguchi N, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Mariani L, Giangaspero F, Tanaka Y, Nakazato Y, Vital A, Mittelbronn M, Perry A, Ohgaki H (2012) Frequent BRAF gain in low-grade diffuse gliomas with 1p/19q loss. Brain Pathol 22(6):834–840. doi:10.​1111/​j.​1750-3639.​2012.​00601.​x PubMedCrossRef
18.
Zurück zum Zitat Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, Pfister S, von Deimling A, Hartmann C (2009) Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 118(3):401–405. doi:10.1007/s00401-009-0550-z PubMedCrossRef Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, Pfister S, von Deimling A, Hartmann C (2009) Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 118(3):401–405. doi:10.​1007/​s00401-009-0550-z PubMedCrossRef
19.
Zurück zum Zitat Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM, Ichimura K, Collins VP (2008) Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68(21):8673–8677. doi:10.1158/0008-5472.CAN-08-2097 PubMedCrossRef Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM, Ichimura K, Collins VP (2008) Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68(21):8673–8677. doi:10.​1158/​0008-5472.​CAN-08-2097 PubMedCrossRef
20.
Zurück zum Zitat Tian Y, Rich BE, Vena N, Craig JM, Macconaill LE, Rajaram V, Goldman S, Taha H, Mahmoud M, Ozek M, Sav A, Longtine JA, Lindeman NI, Garraway LA, Ligon AH, Stiles CD, Santagata S, Chan JA, Kieran MW, Ligon KL (2011) Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. J Mol Diagn 13(6):669–677. doi:10.1016/j.jmoldx.2011.07.002 PubMedCrossRef Tian Y, Rich BE, Vena N, Craig JM, Macconaill LE, Rajaram V, Goldman S, Taha H, Mahmoud M, Ozek M, Sav A, Longtine JA, Lindeman NI, Garraway LA, Ligon AH, Stiles CD, Santagata S, Chan JA, Kieran MW, Ligon KL (2011) Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. J Mol Diagn 13(6):669–677. doi:10.​1016/​j.​jmoldx.​2011.​07.​002 PubMedCrossRef
22.
Zurück zum Zitat Mendelsohn J, Howley PM, Israel MA, Gray JW, Thompson CB (eds) (2008) The molecular basis of cancer, 3rd edn. Elsevier Science, Philadelphia Mendelsohn J, Howley PM, Israel MA, Gray JW, Thompson CB (eds) (2008) The molecular basis of cancer, 3rd edn. Elsevier Science, Philadelphia
23.
Zurück zum Zitat Hawkins C, Walker E, Mohamed N, Zhang C, Jacob K, Shirinian M, Alon N, Kahn D, Fried I, Scheinemann K, Tsangaris E, Dirks P, Tressler R, Bouffet E, Jabado N, Tabori U (2011) BRAF–KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res 17(14):4790–4798. doi:10.1158/1078-0432.CCR-11-0034 PubMedCrossRef Hawkins C, Walker E, Mohamed N, Zhang C, Jacob K, Shirinian M, Alon N, Kahn D, Fried I, Scheinemann K, Tsangaris E, Dirks P, Tressler R, Bouffet E, Jabado N, Tabori U (2011) BRAF–KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res 17(14):4790–4798. doi:10.​1158/​1078-0432.​CCR-11-0034 PubMedCrossRef
24.
Zurück zum Zitat Kandala G, Bannykh S, Fan S, Baden K, Pau A, Baden L, Fournier P, Thorpe E, Porpora K, Mirocha J, Kawachi K, Riley-Portuges A, Lopategui J (2012) Pilocytic astrocytomas with infiltrating patterns of growth carry a high rate of BRAF V600E mutation. Paper presented at the Modern Pathology Kandala G, Bannykh S, Fan S, Baden K, Pau A, Baden L, Fournier P, Thorpe E, Porpora K, Mirocha J, Kawachi K, Riley-Portuges A, Lopategui J (2012) Pilocytic astrocytomas with infiltrating patterns of growth carry a high rate of BRAF V600E mutation. Paper presented at the Modern Pathology
25.
Zurück zum Zitat Lang FF, Miller DC, Pisharody S, Koslow M, Newcomb EW (1994) High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas. Oncogene 9(3):949–954PubMed Lang FF, Miller DC, Pisharody S, Koslow M, Newcomb EW (1994) High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas. Oncogene 9(3):949–954PubMed
26.
Zurück zum Zitat Patt S, Gries H, Giraldo M, Cervos-Navarro J, Martin H, Janisch W, Brockmoller J (1996) p53 gene mutations in human astrocytic brain tumors including pilocytic astrocytomas. Hum Pathol 27(6):586–589PubMedCrossRef Patt S, Gries H, Giraldo M, Cervos-Navarro J, Martin H, Janisch W, Brockmoller J (1996) p53 gene mutations in human astrocytic brain tumors including pilocytic astrocytomas. Hum Pathol 27(6):586–589PubMedCrossRef
27.
Zurück zum Zitat Hayes VM, Dirven CM, Dam A, Verlind E, Molenaar WM, Mooij JJ, Hofstra RM, Buys CH (1999) High frequency of TP53 mutations in juvenile pilocytic astrocytomas indicates role of TP53 in the development of these tumors. Brain Pathol 9(3):463–467PubMedCrossRef Hayes VM, Dirven CM, Dam A, Verlind E, Molenaar WM, Mooij JJ, Hofstra RM, Buys CH (1999) High frequency of TP53 mutations in juvenile pilocytic astrocytomas indicates role of TP53 in the development of these tumors. Brain Pathol 9(3):463–467PubMedCrossRef
28.
Zurück zum Zitat Scheithauer BW, Hawkins C, Tihan T, VandenBerg SR, Burger PC (2007) Pilocytic astrocytoma. In: Louis D, Ohgaki H, Wiestler O, Cavenee W (eds) WHO classification of tumours of the central nervous system, 4th edn. WHO Press, Geneva, p 309 Scheithauer BW, Hawkins C, Tihan T, VandenBerg SR, Burger PC (2007) Pilocytic astrocytoma. In: Louis D, Ohgaki H, Wiestler O, Cavenee W (eds) WHO classification of tumours of the central nervous system, 4th edn. WHO Press, Geneva, p 309
29.
Zurück zum Zitat Ishii N, Sawamura Y, Tada M, Daub DM, Janzer RC, Meagher-Villemure M, de Tribolet N, Van Meir EG (1998) Absence of p53 gene mutations in a tumor panel representative of pilocytic astrocytoma diversity using a p53 functional assay. Int J Cancer 76(6):797–800PubMedCrossRef Ishii N, Sawamura Y, Tada M, Daub DM, Janzer RC, Meagher-Villemure M, de Tribolet N, Van Meir EG (1998) Absence of p53 gene mutations in a tumor panel representative of pilocytic astrocytoma diversity using a p53 functional assay. Int J Cancer 76(6):797–800PubMedCrossRef
30.
Zurück zum Zitat Jha P, Suri V, Singh G, Purkait S, Pathak P, Sharma V, Sharma MC, Suri A, Gupta D, Mahapatra AK, Sarkar C (2011) Characterization of molecular genetic alterations in GBMs highlights a distinctive molecular profile in young adults. Diagn Mol Pathol 20(4):225–232. doi:10.1097/PDM.0b013e31821c30bc PubMedCrossRef Jha P, Suri V, Singh G, Purkait S, Pathak P, Sharma V, Sharma MC, Suri A, Gupta D, Mahapatra AK, Sarkar C (2011) Characterization of molecular genetic alterations in GBMs highlights a distinctive molecular profile in young adults. Diagn Mol Pathol 20(4):225–232. doi:10.​1097/​PDM.​0b013e31821c30bc​ PubMedCrossRef
31.
32.
Zurück zum Zitat Kosel S, Scheithauer BW, Graeber MB (2001) Genotype-phenotype correlation in gemistocytic astrocytomas. Neurosurgery 48(1):187–193 discussion 193–184PubMedCrossRef Kosel S, Scheithauer BW, Graeber MB (2001) Genotype-phenotype correlation in gemistocytic astrocytomas. Neurosurgery 48(1):187–193 discussion 193–184PubMedCrossRef
33.
Zurück zum Zitat Kleihues P, Burger PC, Aldape KD, Brat DJ, Biernat W, Bigner DD, Nakazato Y, Plate Y, Giangaspero F, von Deimling A, Ohgaki H, Cavenee W (2007) Glioblastoma. In: Louis D, Ohgaki H, Wiestler O, Cavenee W (eds) WHO classification of tumours of the central nervous system, 4th edn. WHO Press, Geneva, p 309 Kleihues P, Burger PC, Aldape KD, Brat DJ, Biernat W, Bigner DD, Nakazato Y, Plate Y, Giangaspero F, von Deimling A, Ohgaki H, Cavenee W (2007) Glioblastoma. In: Louis D, Ohgaki H, Wiestler O, Cavenee W (eds) WHO classification of tumours of the central nervous system, 4th edn. WHO Press, Geneva, p 309
34.
Zurück zum Zitat Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Cosper AK, Dias-Santagata D, Nutt CL, Iafrate AJ, Louis DN (2011) A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53. J Neuropathol Exp Neurol 70(2):110–115. doi:10.1097/NEN.0b013e31820565f9 PubMedCrossRef Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Cosper AK, Dias-Santagata D, Nutt CL, Iafrate AJ, Louis DN (2011) A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53. J Neuropathol Exp Neurol 70(2):110–115. doi:10.​1097/​NEN.​0b013e31820565f9​ PubMedCrossRef
Metadaten
Titel
The differential diagnosis of pilocytic astrocytoma with atypical features and malignant glioma: an analysis of 16 cases with emphasis on distinguishing molecular features
verfasst von
Matthew D. Cykowski
Richard A. Allen
Angela C. Kanaly
Kar-Ming Fung
Roxanne Marshall
Arie Perry
Ethan D. Stolzenberg
S. Terence Dunn
Publikationsdatum
01.12.2013
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 3/2013
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-013-1249-5

Weitere Artikel der Ausgabe 3/2013

Journal of Neuro-Oncology 3/2013 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.